Abstract
Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Current Alzheimer Research
Title: Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Volume: 5 Issue: 5
Author(s): James G. McLarnon and Jae K. Ryu
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Abstract: Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Export Options
About this article
Cite this article as:
McLarnon G. James and Ryu K. Jae, Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908874
DOI https://dx.doi.org/10.2174/156720508785908874 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Current Neuropharmacology Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science Editorial [Hot Topic:Nicotinamide Adenine Dinucleotide Biology and Disease(Executive Editor: W. Todd Penberthy)]
Current Pharmaceutical Design Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis
Current Neuropharmacology Integrative Health Services in School Health Clinics
Adolescent Psychiatry Depression and Anxiety in Patients with COPD: A Focus on Psychological Treatments in Ambulatory Care Settings
Current Respiratory Medicine Reviews Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy
CNS & Neurological Disorders - Drug Targets Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research <i>Lactobacillus Rhamnosus</i> UBLR-58 and Diclofenac Potentiate the Anti- Alzheimer Activity of Curcumin in Mice
Current Enzyme Inhibition Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Current Alzheimer Research Secondary Prevention of Ischemic Stroke
Current Drug Targets Editorial (Thematic Issue: Mitochondria and Subcellular Organelles as Treatment Targets Against Pathological Conditions)
Current Pharmaceutical Design Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets GABAergic Functions and Depression: From Classical Therapies to Herbal Medicine
Current Drug Targets - CNS & Neurological Disorders Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Alterations of the X Chromosome in Lymphocytes of Alzheimer’s Disease Patients
Current Alzheimer Research Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets